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Introduction
The NPM1 gene is frequently altered in hematological malignancies. 1 In acute myeloid leukemia (AML), NPM1 is mainly disrupted by C-terminus mutations, causing aberrant cytoplasmic expression of the NPM1 protein.
2 NPM1-mutated AML has distinctive clinicopathologic and molecular features. Most notably, the mutation is closely associated with normal karyotype and relatively favorable prognosis in the absence of FLT3-internal tandem duplication (ITD). 3 While genotyping the NPM1 mutations, a polymorphic nucleotide T deletion (delT) at position 1,146 of the NPM1 3'-untranslated region (UTR) was reported in 60-70% of AML patients. 4, 5 However, the significance of this polymorphism was unclear. Previous studies have shown that polymorphisms in other genes including W T1 and IDH1 can affect AML prognosis in addition to mutations in the cognate genes. 6, 7 Here, we revealed that the homozygous state of the NPM1 delT polymorphism had important clinical and biological implications in AML involving an illegitimate microRNA (miRNA) regulation. patients were treated with the standard cytarabine plus daunorubicin 7+3 induction chemotherapy. 8 Patients who achieved complete remission (CR) were then given consolidation treatment stratified by cytogenetics. Patients with non-favorable cytogenetics were referred for assessment of allogeneic stem cell transplantation.
Design and methods

Patients
Patients who were not eligible for transplantation and those with favorable cytogenetics were given high-dose cytarabine-based chemotherapy for consolidation. Normal bone marrow (BM) and peripheral blood samples were obtained from healthy donors who had no prior history of malignancy.
Cell culture
Cell lines were cultured in RPMI-1640 medium containing 10% fetal bovine serum.
Cytogenetic and mutational studies
Cytogenetics were classified into favorable, intermediate, and adverse according to the U.K. MRC classification. 12, 13 Intermediate/adverse cytogenetics were hereafter collectively referred to as non-favorable. Patients with unknown cytogenetics were screened for the presence (favorable) or absence (non-favorable) of
RUNX 1-ETO, CBFB-MY H11
and PML-RA RA fusion transcripts. 10 Mutation analysis of FLT3-ITD, KIT (exons 8 and 17), NPM1 (C-terminus and the delT polymorphism), and CEBPA was performed as previously described. 10 Exon 4 of IDH1 (R132) and IDH2 (R140 and R172) were analyzed by direct sequencing. Primer sequences are provided in Online Supplementary Table S3 .
Constructs, transfection, and luciferase reporter assays
Full-length NPM1 3'-UTR carrying the wild-type (pmirGLO-3'UTR-WT) or delT (pmirGLO-3'UTR-delT) genotype was cloned into the dual-luciferase pmirGLO vector (Promega), which co-expresses Renilla luciferase for normalization of transfection efficiency. pmirGLO-WT×3 and pmirGLO-delT×3 were prepared by cloning of the annealed oligonucleotides NPM1-WT×3-F/NPM1-WT×3-R and 
Quantitative RT-PCR (qRT-PCR)
RNA was extracted using TRIzol (Life Technologies). qRT-PCR was performed using TaqMan assays (Life Technologies). NPM1 levels were normalized to GA PDH, and miRNAs normalized to RNU48. Relative expression was calculated by 2 -ΔΔCt .
Western blotting
Western blotting was performed as previously described using NPM1 and β-tubulin antibodies (Cell Signaling).
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Statistical analysis
Overall survival (OS) and relapse-free survival (RFS) were defined as previously described. 
P=0.019) than patients with a non-homozygous genotype (Figure 1 C-D). CR rates
were similar between the two groups (83% vs 81%, P=1.000). The homozygous delT genotype remained prognostic for poorer RFS (P=0.028) in multivariate analysis (Table 1) However, when patients with FLT3-ITD (n=7) and KIT mutations (n=5), the two molecular markers reported to correlate with high relapse risk in childhood AML, 15 were excluded, a significant association between homozygous delT and poorer RFS (P=0.032) was noted. The association with OS was not statistically significant (P=0.106).
The delT polymorphism showed no significant correlation with any clinicopathologic and molecular parameters in the adult and childhood patient cohorts (Supplementary Table S2 ).
Polymorphisms within 3'-UTR might modify miRNA-mediated gene regulation. Using the PITA algorithm, 16 we found that the delT created three putative binding sites for miR-337-5p, miR-887, and miR-553 ( Figure 2A ). To investigate the potential relevance of these miRNAs in regulating NPM1, we first examined their expression in BM from patients with different AML subtypes. All the 16 AML samples and 10 normal BM expressed detectable levels of miR-337-5p and miR-887
( Figure 2B ). In contrast, none of the BM examined (16 patients and 11 normal)
showed miR-553 expression (data not shown). Thus, miR-337-5p and miR-887 were selected for functional validation using luciferase reporter assays in HeLa, which expressed barely detectable levels of the two miRNAs (data not shown). Cotransfection of pre-miR-337-5p exerted a dose-dependent repressive effect on the NPM1 3'-UTR harboring the delT ( Figure 2C and Supplementary Figure S2 ). In contrast, no effect on the 3'-UTR-delT construct was observed when pre-miR-887 was used. Moreover, co-transfection of these two miRNA precursors had no effect on the wild-type 3'-UTR construct ( Figure 2C ). To validate this finding, we created two additional constructs, each containing three tandem copies of the delT (pmirGLOdelT×3) or wild-type (pmirGLO-WT×3) sequences. Concordantly, co-transfection with pre-miR-337-5p but not pre-miR-887 drastically repressed the pmirGLO-delTx3 construct ( Figure 2C ). We next transfected K562, U937 and HeLa cells with premiR-337-5p to investigate the effect on endogenous NPM1 expression. These cell lines carried the homozygous delT, heterozygous delT and wild-type genotypes, respectively, and expressed barely detectable levels of miR-337-5p (data not shown).
Transfection of pre-miR-337-5p reduced both NPM1 mRNA and protein levels in K562 cells harboring the homozygous delT polymorphism ( Figure 2D ). In contrast, no apparent effect on NPM1 expression was observed in U937 and HeLa cells.
Collectively, these findings indicate that the delT caused illegitimate repression of NPM1 by miR-337-5p. We next compared NPM1 transcript levels in AML patients with or without homozygous delT. Since NPM1 is ubiquitously and abundantly expressed, 1 only patients whose BM contained at least 80% of blasts were selected for analysis. As shown in Figure 2E , NPM1 levels were significantly reduced in the homozygous delT group as compared to the non-homozygous group. Importantly, those patients with lower NPM1 expression were also found to have poorer outcomes than those with higher NPM1 expression (Supplementary Figure S3) . Notably, a significant inverse relationship between NPM1 and miR-337-5p levels was observed in patients carrying the homozygous delT genotype but not in patients carrying the other genotypes ( Figure 2F ). Figure S4) . Indeed, we noticed that the normal samples had markedly higher NPM1 levels (~7.3-fold) than the AML patient samples while miR-337-5p expression was similar between the two groups. Since the endogenous level of the target mRNA is an important determinant of miRNA regulation, 21 these findings implicate potential differential regulation of NPM1 expression in normal and AML leukemic cells. To date, very little is known about the role of miR-337-5p. It was shown that the miRNA might be involved in the regulation of the tyrosine kinase gene LY N in B-cell chronic lymphocytic leukemia.
NPM1-mutated
22
The similar frequencies of the delT polymorphism between adult AML patients and normal adults suggested that the polymorphism might not predispose to leukemia. Likewise, the cytoplasmic NPM1 mutant also failed to cause AML in transgenic mice, suggesting the need for cooperating mutations. 23 On the other hand, our findings indicated that the delT in homozygous state had negative impacts on AML outcome. Although the mechanisms by which the delT impacts outcome are unclear, it is possible that the delT-associated reduction in NPM1 expression may cause centrosome amplification and genomic instability and promote tumorigenicity of the leukemic cells. 1 Another potential mechanism is that the delT-harboring NPM1 
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